This module reviews gastrointestinal adverse events and switching between GLP-1 receptor agonists, which are two of the most common challenges faced by healthcare professionals when managing patients with obesity. Data on gastrointestinal events from the STEP trials is presented. The ‘three E’ proposal for the management of gastrointestinal side effects is discussed and useful tips that you can use to help patients manage gastrointestinal side effects are provided. The module also covers the reasons for patients wanting to switch to a different GLP-1 receptor agonist and practical advice that you can use to help them when switching.

At the end of this module, you will understand about gastrointestinal side effects with semaglutide 2.4 mg and how to help your patients manage these side effects. You will also be familiar with a set of practical pointers to help your patients when switching between GLP-1 receptor agonists.